Cited by Marburg Virus Reaches Rwanda: How Close Are We to a Vaccine Solution?

Post COVID-19 era: Re-emergence of known and future (X) viral pathogens DOI

Pryanka Thakur,

Vikram Thakur,

Monika Sapra

et al.

Vacunas (English Edition), Journal Year: 2024, Volume and Issue: 25(3), P. 403 - 414

Published: July 1, 2024

Language: Английский

Citations

Control strategies for emerging infectious diseases: Crimean‐Congo hemorrhagic fever management DOI

Shriyansh Srivastava, Sachin Kumar, Pramod Kumar Sharma

et al.

Health Science Reports, Journal Year: 2024, Volume and Issue: 7(9)

Published: Sept. 1, 2024

Abstract Background and Aims Crimean‐Congo Hemorrhagic Fever (CCHF) is a significant public health concern transmitted by ticks. This study seeks to thoroughly grasp the epidemiology transmission patterns of CCHF, which caused CCHF virus (CCHFV), member Nairovirus genus in Bunyaviridae family. Methods The investigates global distribution endemicity its mortality rates, modes (including tick bites, contact with infected animal blood, limited person‐to‐person transmission), factors influencing prevalence across different regions. Genetic diversity within CCHFV impact on dynamics are explored, along efforts control disease through prevention, antiviral treatment, development vaccines diagnostics. Results exhibits widespread distribution, particularly Middle East, Africa, Asia, Eastern Europe, an overall rate approximately 30% case fatality ranging from 10% 40%. Transmission occurs primarily bites transmission. Livestock workers, slaughterhouse employees, herders endemic areas most affected their frequent interaction sick animals contributes variations dynamics, complicating efforts. Antiviral ribavirin shows efficacy treating infection. Conclusion underscores importance further research understand enzootic environment, routes, genetic for effective measures, including vaccines, treatment options,

Language: Английский

Citations

Lysosome-Associated Membrane Protein Targeting Strategy Improved Immunogenicity of Glycoprotein-Based DNA Vaccine for Marburg Virus DOI

Xiyang Zhang,

Yubo Sun,

Junqi Zhang

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(9), P. 1013 - 1013

Published: Sept. 4, 2024

Marburg hemorrhagic fever (MHF) is a fatal infectious disease caused by virus (MARV) infection, and MARV has been identified as priority pathogen for vaccine development the WHO. The glycoprotein (GP) of mediates viral adhesion invasion host cells therefore can be used an effective target development. Moreover, DNA vaccines have unique advantages, such simple construction processes, low production costs, few adverse reactions, but their immunogenicity may decrease due to poor absorption rate plasmids. Lysosome-associated membrane protein 1 (LAMP1) direct antigens lysosomes endosomes great potential improving nucleic acid vaccines. Therefore, we constructed based on codon-optimized GP (ID MF939097.1) fused with LAMP1 explored effect LAMP targeting strategy vaccine. ELISA, ELISpot, flow cytometry revealed that introduction into candidate improved humoral cellular immune response, enhanced secretion cytokines, established long-term protection. Transcriptome analysis significantly enriched antigen processing presentation-related pathways, especially MHC class II-related pathway, in Our study broadens strategic vision design provides promising MHF prevention.

Language: Английский

Citations

Construction and evaluation of glycoprotein-based nucleic acid vaccines for Marburg virus DOI

Xiyang Zhang,

Yubo Sun,

Jiaxing Zhang

et al.

Medical Microbiology and Immunology, Journal Year: 2024, Volume and Issue: 214(1)

Published: Nov. 28, 2024

Language: Английский

Citations

Marburg Virus Reaches Rwanda: How Close Are We to a Vaccine Solution? DOI

Olivier Sibomana, Clyde Moono Hakayuwa,

Jildas Munyantore

et al.

International Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 107371 - 107371

Published: Dec. 1, 2024

Language: Английский

Citations